Evoke Pharma, Inc. (EVOK) Stock Rating Reaffirmed by FBR & Co
Evoke Pharma, Inc. (NASDAQ:EVOK)‘s stock had its “buy” rating reissued by research analysts at FBR & Co in a research note issued on Thursday, MarketBeat reports. They presently have a $10.00 target price on the specialty pharmaceutical company’s stock. FBR & Co’s price objective indicates a potential upside of 190.70% from the company’s previous close.
Other equities analysts also recently issued reports about the stock. Seaport Global Securities reiterated a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a report on Friday, October 6th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a report on Monday, September 18th. Northland Securities reiterated a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a report on Wednesday. Zacks Investment Research upgraded shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a report on Thursday, October 12th. Finally, ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Evoke Pharma presently has an average rating of “Buy” and a consensus target price of $8.86.
Evoke Pharma (NASDAQ EVOK) traded up 2.08% during mid-day trading on Thursday, hitting $3.44. The company had a trading volume of 72,965 shares. The stock’s market capitalization is $52.93 million. Evoke Pharma has a 1-year low of $1.35 and a 1-year high of $4.55. The stock has a 50 day moving average price of $3.35 and a 200-day moving average price of $2.77.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.15). During the same quarter in the prior year, the company posted ($0.41) EPS. On average, analysts forecast that Evoke Pharma will post ($0.87) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Evoke Pharma, Inc. (EVOK) Stock Rating Reaffirmed by FBR & Co” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/22/evoke-pharma-inc-evok-stock-rating-reaffirmed-by-fbr-co.html.
An institutional investor recently raised its position in Evoke Pharma stock. State Treasurer State of Michigan increased its holdings in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 37.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 400,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 108,034 shares during the period. State Treasurer State of Michigan owned 2.60% of Evoke Pharma worth $1,024,000 as of its most recent SEC filing. 12.88% of the stock is currently owned by institutional investors.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.